Brooks Laboratories Ltd announced credit rating actions from multiple agencies, with CARE Ratings Limited upgrading its Long-term Bank Facilities to CARE BB+; Stable from CARE BB; Stable and its Short-term Bank Facilities to CARE A4+ from CARE A4, while maintaining the rating on Fund-based - LT-Cash Credit at CARE BB+; Stable and Non-fund-based - ST-BG/LC at CARE A4+, with a separate maintenance of CARE A4 on November 11, 2025, for Non-fund-based - ST-BG/LC, and CARE BB-; Stable and CARE BB-; Positive on prior dates of November 7, 2024, and October 31, 2023, respectively; CARE Ratings Ltd. also upgraded Long-term bank facilities to CARE BB+; Stable and Short-term bank facilities to CARE A4+ from CARE BB and CARE A4, respectively, noting a modest scale of operations at Rs 86.26 crore in FY26 and referencing instruments including Corporate Bonds and Debentures and Commercial Papers, alongside Guaranteed bank debt of Rs 116.77 crore and Outstanding CG exposure of Rs 48.15 crore, with a target revenue of ~Rs 150 crore in FY29; furthermore, CARE Ratings Limited (Care Edge Ratings) has assigned a Stable outlook to the Manufacturing Business in anticipation of a proposed demerger into Abridge Speciality Limited (ASL), with positive and negative sensitivity triggers based on TOI and PBILDT performance, while CareEdge Ratings clarified that its ratings represent opinions on the likelihood of timely payment.